- Home
- ARR vs CGON Comparison
ARR vs CGON Comparison
Compare ARR & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARR
- CGON
- Stock Information
- Founded
- ARR 2008
- CGON 2010
- Country
- ARR United States
- CGON United States
- Employees
- ARR N/A
- CGON N/A
- Industry
- ARR Real Estate Investment Trusts
- CGON
- Sector
- ARR Real Estate
- CGON
- Exchange
- ARR Nasdaq
- CGON NYSE
- Market Cap
- ARR 1.4B
- CGON 1.3B
- IPO Year
- ARR N/A
- CGON 2024
- Fundamental
- Price
- ARR $16.21
- CGON $25.62
- Analyst Decision
- ARR Hold
- CGON Strong Buy
- Analyst Count
- ARR 5
- CGON 10
- Target Price
- ARR $21.00
- CGON $64.00
- AVG Volume (30 Days)
- ARR 2.3M
- CGON 1.4M
- Earning Date
- ARR 07-23-2025
- CGON 05-13-2025
- Dividend Yield
- ARR 17.77%
- CGON N/A
- EPS Growth
- ARR N/A
- CGON N/A
- EPS
- ARR N/A
- CGON N/A
- Revenue
- ARR $44,778,000.00
- CGON $662,000.00
- Revenue This Year
- ARR $532.77
- CGON N/A
- Revenue Next Year
- ARR $15.62
- CGON $12,387.03
- P/E Ratio
- ARR N/A
- CGON N/A
- Revenue Growth
- ARR 41.14
- CGON 224.51
- 52 Week Low
- ARR $13.18
- CGON $14.80
- 52 Week High
- ARR $21.93
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- ARR 48.11
- CGON 53.27
- Support Level
- ARR $15.61
- CGON $24.79
- Resistance Level
- ARR $16.88
- CGON $26.60
- Average True Range (ATR)
- ARR 0.30
- CGON 1.39
- MACD
- ARR -0.05
- CGON -0.01
- Stochastic Oscillator
- ARR 36.06
- CGON 48.52
About ARR ARMOUR Residential REIT Inc.
ARMOUR Residential REIT Inc operate in the U.S. and invest in fixed rate residential, adjustable rate and hybrid adjustable rate residential MBS issued or guaranteed by U.S. GSEs or guaranteed by Ginnie Mae. It also invest in U.S. Treasury Securities and money market instruments.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.